Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kevin C. Grega is active.

Publication


Featured researches published by Kevin C. Grega.


Bioorganic & Medicinal Chemistry | 2001

Carbon–carbon-linked (pyrazolylphenyl)oxazolidinones with antibacterial activity against multiple drug resistant gram-positive and fastidious gram-negative bacteria

Chi Sing Lee; Debra A. Allwine; Michael R. Barbachyn; Kevin C. Grega; Lester A. Dolak; Charles W. Ford; Randy M. Jensen; Eric P. Seest; Judith C. Hamel; Ronda D. Schaadt; Douglas Stapert; Betty H. Yagi; Gary E. Zurenko; Michael J Genin

In an effort to expand the spectrum of activity of the oxazolidinone class of antibacterial agents to include Gram-negative bacteria, a series of new carbon-carbon linked pyrazolylphenyl analogues has been prepared. The alpha-N-substituted methyl pyrazole (10alpha) in the C3-linked series exhibited very good Gram-positive activity with MICs <or=0.5-1 microg/mL and moderate Gram-negative activity with MICs=2-8 microg/mL against Haemophilus influenzae and Moraxella catarrhalis. This analogue was also found to have potent in vivo activity with an ED(50)=1.9 mg/kg. Beta-substitution at the C3-linked pyrazole generally results in a loss of activity. The C4-linked pyrazoles are slightly more potent than their counterparts in the C3-linked series. Most of the analogues in the C4-linked series exhibited similar levels of activity in vitro, but lower levels of activity in vivo than 10alpha. In addition, incorporation of a thioamide moiety in selected C4-linked pyrazole analogues results in an enhancement of in vitro activity leading to compounds several times more potent than eperezolid, linezolid and vancomycin. The thioamide of the N-cyanomethyl pyrazole analogue (34) exhibited an exceptional in vitro activity with MICs of <or= 0.06-0.25 microg/mL against Gram-positive pathogens and with MICs of 1 microg/mL against fastidious Gram-negative pathogens.


Bioorganic & Medicinal Chemistry Letters | 1996

Synthesis and antibacterial activity of new tropone-substituted phenyloxazolidinone antibacterial agents 2. Modification of the phenyl ring — the potentiating effect of fluorine substitution on in vivo activity

Michael R. Barbachyn; Dana S. Toops; Kevin C. Grega; Susan K. Hendges; Charles W. Ford; Gary E. Zurenko; Judith C. Hamel; Jonda D. Schaadt; Douglas Stapert; Betty H. Yagi; Jerry M. Buysse; William F. Demyan; James O. Kilburn; Suzanne E. Glickman

Abstract Various electron-withdrawing groups were incorporated into the meta position of tropone-substituted 3-phenyl-2-oxazolidinones and their influence on antibacterial activity examined. Consideration of in vitro and in vivo test results indicated that one or two fluorine atoms flanking the para tropone appendage is the optimum arrangement for these compounds. Synthetic routes to enantiomerically enriched analogues are reported.


Advances in Experimental Medicine and Biology | 1998

Design, Synthesis, and Evaluation of Novel Oxazolidinone Antibacterial Agents Active Against Multidrug-Resistant Bacteria

Michael R. Barbachyn; Steven J. Brickner; Robert C. Gadwood; Stuart A. Garmon; Kevin C. Grega; Douglas K. Hutchinson; Kiyotaka Munesada; Robert J. Reischer; Mikio Taniguchi; Lisa Marie Thomasco; Dana S. Toops; Hiromi Yamada; Charles W. Ford; Gary E. Zurenko

Throughout the human experience, diseases caused by pathogenic bacteria have exerted an enormous negative impact on society. Today, for example, approximately one third of the world’s population is infected with Mycobacterium tuberculosis and tuberculosis remains the leading cause of death in the world from infectious disease (Bloom, 1994). The emergence of effective antibacterial agents, from penicillin to more contemporary drugs, was initially thought to mark an end to the burden of microbial disease. However, subsequent events have illustrated the resiliency of bacteria to environmental pressures, including the threat of antibacterial agents.


Bioorganic & Medicinal Chemistry Letters | 1996

Synthesis and antibacterial activity of new tropone-substituted phenyloxazolidinone antibacterial agents 1. Identification of leads and importance of the tropone substitution pattern

Michael R. Barbachyn; Dana S. Toops; Debra A. Ulanowicz; Kevin C. Grega; Steven J. Brickner; Charles W. Ford; Gary E. Zurenko; Judith C. Hamel; Ronda D. Schaadt; Douglas Stapert; Betty H. Yagi; Jerry M. Buysse; William F. Demyan; James O. Kilburn; Suzanne E. Glickman

Abstract Incorporation of a substituted tropone moiety into the para position of suitably functionalized 3-phenyl-2-oxazolidinones affords novel and potent antibacterial agents. The effect of the tropone regioisomer and its attendant substituents on antibacterial activity is discussed. Analogues such as 11c and 13b display in vitro and in vivo activity approaching that of the current clinical benchmark, vancomycin.


Journal of Medicinal Chemistry | 2000

Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.

Genin Mj; Debra A. Allwine; Anderson Dj; Michael R. Barbachyn; Emmert De; Stuart A. Garmon; Graber Dr; Kevin C. Grega; Hester Jb; Douglas K. Hutchinson; Joel Morris; Reischer Rj; Charles W. Ford; Gary E. Zurenko; Judith C. Hamel; Ronda D. Schaadt; Douglas Stapert; Betty H. Yagi


Journal of Medicinal Chemistry | 1996

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

Steven J. Brickner; Douglas K. Hutchinson; Michael R. Barbachyn; Peter R. Manninen; Debra A. Ulanowicz; Stuart A. Garmon; Kevin C. Grega; Susan K. Hendges; Dana S. Toops; Charles W. Ford; Gary E. Zurenko


Journal of Medicinal Chemistry | 1996

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.

Michael R. Barbachyn; Douglas K. Hutchinson; Steven J. Brickner; Michael H. Cynamon; James O. Kilburn; Sally P. Klemens; Suzanne E. Glickman; Kevin C. Grega; Susan K. Hendges; Dana S. Toops; Charles W. Ford; Gary E. Zurenko


Journal of Medicinal Chemistry | 1998

Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.

John A. Tucker; Debra A. Allwine; Kevin C. Grega; Michael R. Barbachyn; Jennifer L. Klock; Jenifer L. Adamski; Steven J. Brickner; Douglas K. Hutchinson; Charles W. Ford; Gary E. Zurenko; Robert A. Conradi; Phillip S. Burton; Randy M. Jensen


Journal of Organic Chemistry | 1995

Regioselective Metalation of Fluoroanilines. An Application to the Synthesis of Fluorinated Oxazolidinone Antibacterial Agents

Kevin C. Grega; Michael R. Barbachyn; Steven J. Brickner; Stephen A. Mizsak


Journal of Organic Chemistry | 2001

Oxidative cleavage of 1,3-dicarbonyls to carboxylic acids with oxone.

Scott W. Ashford; Kevin C. Grega

Collaboration


Dive into the Kevin C. Grega's collaboration.

Researchain Logo
Decentralizing Knowledge